HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG MEDICARE BENEFICIARIES INITIATING VENETOCLAX VS. BTKIS FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD STUDY

被引：0
|
作者：
Huntington, S. [1 ]
Manzoor, B. S. [2 ]
Jawaid, D. [2 ]
Puckett, J. [3 ]
Alhasani, H. [2 ]
Ravelo, A. [4 ]
Kamal-Bahl, S. [5 ]
Emechebe, N. [2 ]
Doshi, J. A. [6 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] AbbVie Inc, Chicago, IL USA
[3] COVIA Hlth Solut, Philadelphia, PA USA
[4] Genentech Inc, San Francisco, CA USA
[5] COVIA Hlth Solut, Lansdale, PA USA
[6] Univ Penn, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE158
引用
收藏
页码：S88 / S89
页数：2
相关论文
共 50 条
  • [21] Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States
    Matasar, Matthew J.
    Byfield, Stacey Dacosta
    Blauer-Peterson, Cori
    Montez, Melissa
    Reyes, Carolina
    Masaquel, Anthony
    BLOOD, 2016, 128 (22)
  • [22] A REAL-WORLD COMPARISON OF MORTALITY, HEALTHCARE RESOURCE UTILIZATION, AND COST AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION WITH AND WITHOUT SEPSIS
    Amin, Alpesh
    Nelson, Winnie W.
    Dahdal, David N.
    Dreyfus, Jill
    Wong, Anny C.
    Mohammadi, Iman
    Teigland, Christie
    GASTROENTEROLOGY, 2021, 160 (06) : S362 - S363
  • [23] Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
    Kotmayer, Lili
    Laszlo, Tamas
    Mikala, Gabor
    Kiss, Richard
    Levay, Luca
    Hegyi, Lajos Laszlo
    Grof, Stefania
    Nagy, Tibor
    Barna, Gabor
    Farkas, Peter
    Weisinger, Julia
    Nagy, Zsolt
    Balogh, Alexandra
    Masszi, Tamas
    Demeter, Judit
    Sulak, Adrienn
    Kohl, Zoltan
    Alizadeh, Hussain
    Egyed, Miklos
    Pettendi, Piroska
    Gergely, Lajos
    Plander, Mark
    Pauker, Zsolt
    Masszi, Andras
    Matolcsy, Andras
    Szasz, Robert
    Bodor, Csaba
    Alpar, Donat
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [24] REAL-WORLD COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND COSTS BETWEEN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH FIRST-LINE IBRUTINIB OR ACALABRUTINIB
    Rogers, K. A.
    Qureshi, Z. P.
    Ding, Z.
    Emond, B.
    Gogna, P.
    Lafeuille, M. H.
    Bokun, A.
    Fradley, M.
    VALUE IN HEALTH, 2023, 26 (12) : S63 - S63
  • [25] Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia - A Retrospective Study of a Real-World Setting
    Saiz-Rodriguez, Miriam
    Cuevas, Beatriz
    Alvarez, Rodolfo
    Cuello, Rebeca
    Belen Vidriales, Maria
    Olivier, Carmen
    Recio, Isabel
    Campuzano, Veronica
    Yeguas, Ana
    Cuevas, Victoria
    Javier Diaz-Galvez, Francisco
    Ruano, Teresa
    Avendano, Alejandro
    Duenas, Veronica
    Garcia, Covadonga
    Jose Gonzalez-Lopez, Tomas
    Olazabal, Juan
    Serra, Fe
    De Vicente, Pilar
    Hermida, Gerardo
    Labrador, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S173 - S174
  • [26] Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group
    Sobon, Anita
    Drozd-Sokolowska, Joanna
    Paszkiewicz-Kozik, Ewa
    Poplawska, Lidia
    Morawska, Marta
    Tryc-Szponder, Jagoda
    Bolkun, Lukasz
    Rybka, Justyna
    Pruszczyk, Katarzyna
    Juda, Adrian
    Majeranowski, Alan
    Iskierka-Jazdzewska, Elzbieta
    Steckiewicz, Pawel
    Wdowiak, Kamil
    Budziszewska, Bozena
    Jamroziak, Krzysztof
    Hus, Iwona
    Lech-Maranda, Ewa
    Pula, Bartosz
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2119 - 2126
  • [27] Real World Treatment Patterns, Adverse Events and Healthcare Resource Utilization and Costs Among Chronic Lymphocytic Leukemia (CLL) Patients in the United States
    Kabadi, Shaum
    Le, Lisa
    Byfield, Stacey Dacosta
    Olufade, Temitope O.
    BLOOD, 2018, 132
  • [28] Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A US Real-World Observational Study
    Yang, Xiaoqin
    Laliberte, Francois
    Germain, Guillaume
    Raut, Monika
    Duh, Mei Sheng
    Sen, Shuvayu S.
    Lejeune, Dominique
    Desai, Kaushal D.
    Armand, Philippe
    BLOOD, 2019, 134
  • [29] Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib
    De Nigris, Enrico
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    Farooqui, Mohammed Z. H.
    Gandra, Shravanthi R.
    Laliberte, Francois
    FUTURE ONCOLOGY, 2024, 20 (35) : 2723 - 2735
  • [30] Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy
    Atallah, Ehab L.
    Maegawa, Rodrigo
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Guerin, Annie
    Patwardhan, Pallavi
    BLOOD, 2020, 136
12345